We provide you with 20 years of free, institutional-grade data for VRCA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of VRCA. Explore the full financial landscape of VRCA stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | Open Market Purchase | 321,616 | $7.2 | 2023-12-29 | |
| PERCEPTIVE ADVISORS LLC | Open Market Purchase | 504,652 | $6.17 | 2023-12-26 | |
| PERCEPTIVE ADVISORS LLC | Open Market Purchase | 1,233,931 | $5.97 | 2023-12-19 | |
| Kohler Terry | Sale | -28,084 | $2.93 | $82,286 | 2023-11-16 |
| White Ted | Sale | -33,699 | $2.93 | $98,738 | 2023-11-16 |
| Hayes Christopher G. | Sale | -33,699 | $2.93 | $98,738 | 2023-11-16 |
| Bonaccorso Joe | Sale | -32,846 | $2.93 | $96,239 | 2023-11-16 |
| Goldenberg Gary | Sale | -8,853 | $2.93 | $25,939 | 2023-11-16 |
| Kohler Terry | Grant, award...etc | 62,500 | 2023-08-28 | ||
| Hayes Christopher G. | Grant, award...etc | 75,000 | 2023-08-28 | ||
| Goldenberg Gary | Grant, award...etc | 25,000 | 2023-08-28 | ||
| White Ted | Grant, award...etc | 75,000 | 2023-08-28 | ||
| Bonaccorso Joe | Grant, award...etc | 62,500 | 2023-08-28 | ||
| Hayes Christopher G. | Sale | -33,789 | $4.83 | $163,201 | 2023-07-25 |
| Hayes Christopher G. | Grant, award...etc | 100,000 | 2023-07-25 | ||
| Goldenberg Gary | Sale | -28,699 | $4.83 | $138,616 | 2023-07-25 |
| Goldenberg Gary | Grant, award...etc | 75,000 | 2023-07-25 | ||
| Bonaccorso Joe | Sale | -38,262 | $4.83 | $184,805 | 2023-07-25 |
| Bonaccorso Joe | Grant, award...etc | 100,000 | 2023-07-25 | ||
| White Ted | Sale | -50,677 | $4.83 | $244,770 | 2023-07-25 |
| White Ted | Grant, award...etc | 150,000 | 2023-07-25 | ||
| Manning Paul B | Open Market Purchase | 200,000 | $5.02 | 2023-07-24 | |
| White Ted | Open Market Purchase | 7,500 | $2.1 | 2023-02-21 | |
| Hayes Christopher G. | Open Market Purchase | 7,500 | $3.4 | 2022-07-11 | |
| Manning Paul B | Open Market Purchase | 4,761,904 | $2.1 | 2022-07-05 | |
| Stalfort John A III | Open Market Purchase | 238,095 | $2.1 | 2022-07-05 | |
| White Ted | Open Market Purchase | 23,809 | $2.1 | 2022-07-05 | |
| Goldenberg Gary | Open Market Purchase | 23,809 | $2.1 | 2022-07-05 | |
| Hayes Christopher G. | Open Market Purchase | 5,714 | $2.1 | 2022-07-05 | |
| PERCEPTIVE ADVISORS LLC | Open Market Purchase | 1,428,571 | $2.1 | 2022-07-05 | |
| Manning Paul B | Open Market Purchase | 50,000 | $9.45 | 2021-12-06 | |
| White Ted | Open Market Purchase | 4,000 | $9.95 | 2021-06-07 | |
| Hayes Christopher G. | Open Market Purchase | 2,500 | $9.79 | 2021-06-07 | |
| DAVIS A BRIAN | Open Market Purchase | 5,000 | $9.89 | 2021-06-07 | |
| Manning Paul B | Open Market Purchase | 739,830 | $14.75 | 2021-03-29 | |
| Ballaron Craig | Open Market Purchase | 10,000 | $9.16 | 2020-08-26 | |
| Manning Paul B | Open Market Purchase | 20,000 | $9.09 | 2020-08-21 | |
| Manning Paul B | Open Market Purchase | 10,000 | $8.55 | 2020-08-19 | |
| Manning Paul B | Open Market Purchase | 6,000 | $6.92 | 2020-08-18 | |
| Stalfort Sean | Open Market Purchase | 31,250 | $6.45 | 2020-08-17 | |
| DAVIS A BRIAN | Open Market Purchase | 7,900 | $6.24 | 2020-08-17 | |
| White Ted | Open Market Purchase | 10,661 | $6.28 | 2020-08-17 | |
| Manning Paul B | Open Market Purchase | 158,500 | $6.41 | 2020-08-17 | |
| Nguyen Diem | Initial | 2020-06-11 |
The information provided in this report about VRCA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Verrica Pharmaceuticals Inc(NASDAQ:VRCA) 
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial fo...
Website: http://www.verrica.com
Founded: 2013
Full Time Employees: 17
Sector: Healthcare
Industry: Biotechnology